Dr. Helen I. Torley

Halozyme Therapeutics

Dr. Helen Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry to her roles as President and CEO. Throughout her career, she has led l successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Helen served as executive vice president and chief commercial officer for Onyx Pharmaceuticals. In this role she was responsible for the successful launch of Kyprolis in the US and led the development of Onyx’s commercial capabilities in ex-U.S. markets and in particular, in Europe. She also oversaw the development and commercial collaboration with Bayer on Nexavar® and Stivarga®. In 2018, Helen was awarded the EY Entrepreneur Of The Year® San Diego in the category of Operational Excellence. She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch. B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

Year appointed: 2014